Esperion Therapeutics (ESPR) Earnings Date, Estimates & Call Transcripts → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ESPR Stock Alerts $2.19 +0.10 (+4.78%) (As of 05/10/2024 08:54 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateAug. 6EstimatedActual EPS (Feb. 27) -$0.50 Beat By $0.03 Consensus EPS (Feb. 27) -$0.53 Read Call TranscriptListen to Call Get Esperion Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for ESPR and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueESPR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ESPR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Unstoppable ProsperityCharles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. Esperion Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243($0.38)($0.24)($0.29)Q2 20243($0.25)($0.10)($0.17)Q3 20243($0.20)($0.07)($0.15)Q4 20243($0.20)$0.12($0.08)FY 202412($1.03)($0.29)($0.69)Q1 20251($0.14)($0.14)($0.14)Q2 20251($0.01)($0.01)($0.01)Q3 20251$0.03$0.03$0.03Q4 20251$0.14$0.14$0.14FY 20254$0.02$0.02$0.02Q1 20261$0.40$0.40$0.40ESPR Earnings Date and InformationEsperion Therapeutics last posted its quarterly earnings results on February 27th, 2024. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.03. The company earned $32.25 million during the quarter, compared to analysts' expectations of $26.84 million. Esperion Therapeutics has generated ($0.99) earnings per share over the last year (($0.99) diluted earnings per share). Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.17) to $0.34 per share. Esperion Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off prior year's report dates.Read More Esperion Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/6/2024Estimated)------- 2/27/2024Q4 2023($0.53)($0.50)+$0.03($0.50)$26.84 million$32.25 million 11/7/2023Q3 2023($0.42)($0.37)+$0.05($0.37)$30.84 million$33.97 million 8/1/2023Q2 2023($0.61)($0.46)+$0.15($0.46)$24.64 million$25.79 million 5/9/2023Q1 2023($0.65)($0.79)($0.14)($0.79)$21.97 million$24.30 million 2/21/2023Q4 2022($0.87)($0.76)+$0.11($0.76)$20.60 million$18.18 million 11/1/2022Q3 2022($0.93)($0.81)+$0.12($0.81)$19.83 million$18.98 million Get the Latest News and Ratings for ESPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/2/2022Q2 2022($0.95)($1.05)($0.10)($1.05)$18.62 million$18.80 million 5/3/2022Q1 2022($0.96)($0.93)+$0.03($0.93)$15.41 million$18.84 million 2/22/2022Q4 2021($2.32)($1.77)+$0.55($1.77)$14.48 million$15.40 million 11/2/2021Q3 2021($2.86)($2.62)+$0.24($2.62)$12.31 million$14.41 million 8/3/2021Q2 2021($1.82)($1.67)+$0.15($1.67)$42.16 million$40.70 million Esperion Therapeutics Earnings - Frequently Asked Questions When is Esperion Therapeutics's earnings date? Esperion Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates. Learn more on ESPR's earnings history. Did Esperion Therapeutics beat their earnings estimates last quarter? In the previous quarter, Esperion Therapeutics (NASDAQ:ESPR) reported ($0.50) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.53) by $0.03. Learn more on analysts' earnings estimate vs. ESPR's actual earnings. How can I listen to Esperion Therapeutics's earnings conference call? The conference call for Esperion Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Esperion Therapeutics's conference call transcript? The conference call transcript for Esperion Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Esperion Therapeutics generate each year? Esperion Therapeutics (NASDAQ:ESPR) has a recorded annual revenue of $116.33 million. How much profit does Esperion Therapeutics generate each year? Esperion Therapeutics (NASDAQ:ESPR) has a recorded net income of -$209.25 million. ESPR has generated -$0.99 earnings per share over the last four quarters. What is Esperion Therapeutics's EPS forecast for next year? Esperion Therapeutics's earnings are expected to grow from ($0.17) per share to $0.34 per share in the next year. More Earnings Resources from MarketBeat Related Companies: PepGen Earnings Results Revance Therapeutics Earnings Results Acelyrin Earnings Results Neurogene Earnings Results Lexicon Pharmaceuticals Earnings Results Theravance Biopharma Earnings Results Korro Bio Earnings Results Heron Therapeutics Earnings Results Biomea Fusion Earnings Results Annexon Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:ESPR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
